ORIC Pharmaceuticals Management
Management criteria checks 3/4
ORIC Pharmaceuticals' CEO is Jacob Chacko, appointed in May 2018, has a tenure of 6.67 years. total yearly compensation is $3.15M, comprised of 18.9% salary and 81.1% bonuses, including company stock and options. directly owns 1.1% of the company’s shares, worth $6.62M. The average tenure of the management team and the board of directors is 5.5 years and 4.8 years respectively.
Key information
Jacob Chacko
Chief executive officer
US$3.2m
Total compensation
| CEO salary percentage | 18.9% |
| CEO tenure | 6.7yrs |
| CEO ownership | 1.1% |
| Management average tenure | 5.5yrs |
| Board average tenure | 4.8yrs |
Recent management updates
Recent updates
We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
Dec 12
Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation
Aug 21ORIC Pharmaceuticals Stock: Too Early To Justify This Valuation
Jul 29ORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could Yield Value
Jul 17We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely
May 08ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains
Mar 13We're Not Very Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Rate
Jan 18We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
Sep 27ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans
Jun 14Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth
Jan 24ORIC Pharmaceuticals: Poster Child For The Current Downturn In Biotech
Oct 14Is ORIC Pharmaceuticals (NASDAQ:ORIC) In A Good Position To Deliver On Growth Plans?
Oct 08ORIC Pharmaceuticals GAAP EPS of -$0.51 beats by $0.09
Aug 11ORIC Pharmaceuticals (NASDAQ:ORIC) Is In A Good Position To Deliver On Growth Plans
Jun 24We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely
Mar 08We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
Nov 23We Think ORIC Pharmaceuticals (NASDAQ:ORIC) Can Afford To Drive Business Growth
Aug 05ORIC Pharmaceuticals EPS beats by $0.04
May 06Here's Why We're Not Too Worried About ORIC Pharmaceuticals' (NASDAQ:ORIC) Cash Burn Situation
Apr 16We're Hopeful That ORIC Pharmaceuticals (NASDAQ:ORIC) Will Use Its Cash Wisely
Jan 01
Oric Pharma starts expansion phase of mid-stage solid tumor study with ORIC-101
Dec 21Oric Pharma prices stock offering at $23
Nov 13CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$120m |
| Jun 30 2024 | n/a | n/a | -US$111m |
| Mar 31 2024 | n/a | n/a | -US$102m |
| Dec 31 2023 | US$3m | US$596k | -US$101m |
| Sep 30 2023 | n/a | n/a | -US$93m |
| Jun 30 2023 | n/a | n/a | -US$93m |
| Mar 31 2023 | n/a | n/a | -US$90m |
| Dec 31 2022 | US$4m | US$572k | -US$89m |
| Sep 30 2022 | n/a | n/a | -US$91m |
| Jun 30 2022 | n/a | n/a | -US$85m |
| Mar 31 2022 | n/a | n/a | -US$85m |
| Dec 31 2021 | US$7m | US$536k | -US$79m |
| Sep 30 2021 | n/a | n/a | -US$84m |
| Jun 30 2021 | n/a | n/a | -US$91m |
| Mar 31 2021 | n/a | n/a | -US$81m |
| Dec 31 2020 | US$6m | US$489k | -US$74m |
| Sep 30 2020 | n/a | n/a | -US$54m |
| Jun 30 2020 | n/a | n/a | -US$35m |
| Mar 31 2020 | n/a | n/a | -US$30m |
| Dec 31 2019 | US$672k | US$456k | -US$27m |
| Dec 31 2018 | US$2m | US$290k | -US$21m |
Compensation vs Market: Jacob's total compensation ($USD3.15M) is above average for companies of similar size in the US market ($USD2.26M).
Compensation vs Earnings: Jacob's compensation has been consistent with company performance over the past year.
CEO
Jacob Chacko (45 yo)
6.7yrs
Tenure
US$3,153,083
Compensation
Dr. Jacob M. Chacko, M.D., MBA, has been Chief Executive Officer and Director of ORIC Pharmaceuticals, Inc. since May 2018 and has been its President since May 2019. Dr. Chacko joined the ORIC Pharmaceutic...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9.8yrs | US$186.87k | 0.32% $ 1.9m | |
| President | 6.7yrs | US$3.15m | 1.1% $ 6.6m | |
| Chief Financial Officer | 5.3yrs | US$1.45m | 0.15% $ 907.5k | |
| Chief Medical Officer | 6.3yrs | US$1.51m | 0.066% $ 397.5k | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Chief Scientific Officer | 5.5yrs | no data | no data | |
| General Counsel | 4.8yrs | no data | no data | |
| VP & Head of People | 2.3yrs | no data | no data | |
| Senior Vice President of Clinical Development | 5.8yrs | no data | no data | |
| Chief Business Officer | 6.2yrs | no data | no data | |
| Senior VP of Commercial & Medical Affairs | less than a year | no data | no data |
5.5yrs
Average Tenure
57yo
Average Age
Experienced Management: ORIC's management team is seasoned and experienced (5.5 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 9.8yrs | US$186.87k | 0.32% $ 1.9m | |
| President | 6.7yrs | US$3.15m | 1.1% $ 6.6m | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Co-Founder & Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 3.2yrs | US$140.37k | 0% $ 0 | |
| Independent Director | 4.6yrs | US$133.87k | 0.029% $ 174.2k | |
| Independent Director | 4.9yrs | US$147.87k | 0% $ 0 | |
| Independent Director | 3.4yrs | US$141.37k | 0% $ 0 |
4.8yrs
Average Tenure
62.5yo
Average Age
Experienced Board: ORIC's board of directors are considered experienced (4.8 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 19:37 |
| End of Day Share Price | 2025/01/08 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ORIC Pharmaceuticals, Inc. is covered by 13 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Prakhar Agrawal | Cantor Fitzgerald & Co. |
| Yigal Nochomovitz | Citigroup Inc |